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 Myasthenia gravis is an autoimmune disease characterized by antibodies against 
acetylcholine receptors (AChRs) at the neuromuscular junction (NMJ) of skeletal muscle.  
These antibodies interfere with the transmission of nerve impulses resulting in weakness 
and paralysis.  Due to the variability in symptoms and heterogeneity of autoantibody 
production in patients with myasthenia gravis, it is essential to make available the best 
clinical laboratory tests to aid the clinician in diagnosis.  One means by which AChR 
antibodies interfere with nerve impulse transmission is through the effect of antigenic 
modulation, a process in which antibody-bound AChRs on the postsynaptic muscle cell 
membrane are internalized and destroyed.  The current laboratory assay for the detection 
of AChR modulating antibodies involves measuring the reduction of expression of 
radiolabeled AChRs on a human rhabdomyosarcoma (RD) cell line in response to 
exposure to patient serum.   
The goal of this study was to determine the feasibility of detection of AChR 
modulating antibodies by a new flow-cytometric method rather than the current 
radioimmunoassay.  Two cell lines were investigated: the RD cell line which expresses 
fetal AChRs and the DB40 cell line which has been transfected with genes for the 
expression of fetal and adult acetylcholine receptors.  Samples tested included sera from 
120 self-proclaimed healthy individuals and 100 samples submitted for clinical testing, 
iv 
50 of which were AChR antibody positive and 50 of which were AChR antibody 
negative.  Results of the flow-cytometric AChR modulating antibody testing on the RD 
cell line correlated best with results for currently available assays and demonstrated better 
sensitivity and specificity than the current radioimmunoassay.  Results of AChR 
modulating antibody testing on the DB40 cell line showed slightly decreased sensitivity 
and specificity, potentially resulting from defects in receptor metabolism due to gene 
transfection.  Detection of AChR modulating antibodies by flow cytometry is feasible 
and uses an assay format that is more sensitive, specific, and robust with less cost and 
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Myasthenia gravis (MG) is an autoimmune disease characterized by the presence 
of antibodies directed against acetylcholine receptors (AChRs) and occasionally other 
proteins at the neuromuscular junction (NMJ) in skeletal muscle.  These antibodies cause 





 A description of a disorder resembling MG first appeared in 1672 in De Anima 
Brutorum by the anatomist and physician Thomas Willis (1).  Willis described subjects 
who “in the morning are able to walk firmly… or take up any heavy thing, [and] before 
noon the stock of Spirits being spent… are scarce able to move Hand or Foot.”  He went 
on to describe a particular woman who, after speaking at length, would become mute and 
would not recover the ability to speak for several hours.  Willis speculated that the 
paralysis was due to weakness in a force that was carried in the blood that compelled 
muscles to move.  
 Over 200 years passed before the next description of a case likely to have been 
myasthenia gravis.  In 1877 Sir Samuel Wilks, a physician interested in pathology, wrote 
of the case of a girl (age not stated) who died as a result of bulbar paralysis.  Bulbar 
paralysis is a term applied to dysfunction of muscles innervated by several of the cranial 
nerves. Wilks performed an autopsy expecting to find necrosis as a result of infarction, 
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but his findings were significant in that the brainstem appeared healthy.  He attributed her 
death to a case of “hysteria” (1).  
Similar cases of fluctuating and recoverable paralysis were described over the 
next 20 years, and in 1895 Friedrich Jolly described two cases as “myasthenia gravis 
pseudo-paralytica”.  From this point on the term “myasthenia gravis” became the name 
for the disease.  He noted that in individuals where one group of muscles was stimulated 
to exhaustion, other unstimulated muscles in the same individual would exhibit the same 
weakness.  This suggested a circulating factor responsible for the weakness (1).  
 Several other researchers in the first half of the 20th century continued 
investigating the disease and found lymphocytic infiltration of the neuromuscular 
junction, thymic abnormalities, and the discovery by Dr. Mary Broadfoot Walker that 
symptoms improve with administration of prostigmine (1), a reversible 
acetylcholinesterase inhibitor (2).  These findings culminated in a hypothesis put forth by 
John Simpson of the National Hospital in London, England that MG was caused by an 
autoimmune reaction against the neuromuscular junction; thus beginning a more modern 





  The major symptom of MG is weakness in specific groups of voluntary muscles. 
The disease may present clinically in two major ways.  Ocular MG is limited to the 
extraocular and levator palpebrae muscles, while generalized MG is weakness that 
extends beyond the ocular muscles.  The weakness is not present initially and there is no 
generalized fatigue or pain, but muscle weakness becomes profound or almost paralytic 
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after exertion (3). 
Symptoms of MG most frequently initially manifest in relation to vision. Ptosis 
(paralytic closing of the eyelid), diplopia (double vision), and blurred vision are most 
commonly reported.  There is no consensus as to whether either ptosis or diplopia usually 
occurs first, but a slight ptosis may go unnoticed in patients when diplopia is readily 
apparent.  Not all muscles are affected to the same extent, and diplopia may be 
horizontal, vertical, or diagonal (4). 
 Bulbar symptoms are seen in muscles innervated by cranial nerves V, VII, IX, X, 
XI and XII; muscles that control movement of the face, head, and throat.  Bulbar 
symptoms are the second most prevalent relating to the disease. Problems speaking may 
include a nasal voice or difficulty articulating.  Fatigue related to chewing may appear 
and patients may need to hold their mouths closed by hand at the end of a meal.  
Difficulty in swallowing or otherwise controlling the mouth may lead to the sensation 
that food is stuck in the throat, drooling, aspiration of food, regurgitation of liquid 
through the nose (palatal insufficiency), or ventilatory insufficiency.  Weakness of the 
lips may lead to the inability to whistle or kiss and weakness of the tongue may lead to 
atrophy with a distinctive longitudinal triple furrowing pattern (4).  Weakness of the neck 
muscles can present as problems in balancing the head, especially if the patient routinely 
performs work in a bent position.  Constant straining of the neck muscles may cause 
myalgia, normally absent in MG, and may cause the clinician to erroneously search for 
cervical spine pathology (4). 
 Weakness in the trunk is almost never the first symptom, but difficulty breathing 
is often the symptom that causes patients to seek medical attention.  Weakness in the legs 
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often leads to sudden falls, especially on stairs, which brings the possibility of MG to the 
attention of the clinician.  While most patients have both arm and leg symptoms, usually 
one will predominate and differential weakness can be observed on examination (4). 
 Half of all patients present with ocular symptoms at the time of diagnosis, with 
this number increasing to 80% by the end of the first month of illness.  Bulbar symptoms 
are seen in 10% of patients, leg weakness in 10%, generalized weakness in 10%, and 1% 
of patients present with respiratory failure (5). 
Myasthenic crisis is a serious complication of MG characterized by respiratory 
arrest requiring ventilation and other support measures.  Approximately 10-15% of 
patients will experience this crisis within 3 years of diagnosis (6). 
Suspicion of MG does not warrant investigating involvement of the central 
nervous system.  Studies of patients have not shown correlation between symptoms of 
muscle weakness and decrease in mental function.  Also, sera from MG patients 
containing skeletal muscle acetylcholine receptor (AChR) autoantibodies were not shown 





The neuromuscular junction (NMJ) in skeletal muscle resides in a complex 
environment between the axon terminal of a nerve fiber on the presynaptic side and the 
highly folded postsynaptic muscle cell membrane.  The presynaptic and postsynaptic 
membranes are separated by a distance of approximately 20 nm, with the intervening 
space occupied by acetylcholinesterase and other proteoglycans that contribute to 
synaptic stability (7). The total volume of the NMJ is approximately 50 nm3, and the 
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AChRs are clustered at the apices of the folds of the postsynaptic membrane.  Estimates 
on receptor density range from 12,000-24,000 receptors/µm2 of membrane (7,8).  Agrin 
is secreted by the neuron at the NMJ to stimulate receptor clustering.  Agrin is the ligand 
for the Myotube Associated Specificity Component (MASC)/Muscle Specific Kinase 
(MuSK) complex. Rapsyn is the protein that links the cytosolic tails of AChRs and is 
responsible for receptor clustering (8).  Rapsyn and AChRs are present in equimolar 
concentrations in normal muscle cells (7).  When an action potential reaches the terminus 
of the axon, voltage gated calcium channels open in response to membrane depolarization 
and allow influx of calcium ions into the neuron.  The influx of calcium ions causes 
fusion of ACh vesicles in the neuron with the neuronal membrane. Each vesicle contains 
approximately 10,000 ACh molecules, and 50-300 vesicles are released with each 
depolarization.  The ACh released into the synaptic cleft quickly diffuses across the gap 
and binds the AChRs on the postsynaptic membrane apices allowing sodium ions to enter 
the muscle cell and initiate muscle contraction.  Acetylcholinesterase resides in the clefts 
of the postsynaptic folds and hydrolyzes ACh as it enters the clefts.  The clefts act as a 
sink for the ACh to ensure that the AChRs are stimulated only once by each action 
potential (8). 
 The AChRs themselves are pentameric, transmembrane proteins.  The 5 receptor 
subunits are arranged in a rosette around the central ion channel.  There are 17 individual 
receptor subunit types: α1-10, β1-4, γ, δ, and ε. Of the 17 different subunits and all 
possible combinations, only 2 receptor subunit profiles are expressed in human skeletal 
muscle AChRs: fetal receptors contain α1, β1, δ, α1, γ subunits and adult receptors 
contain α1, β1, δ, α1, ε subunits (9).  This difference in fetal and adult receptor structure 
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causes adult AChRs to remain open about 4 milliseconds when stimulated, versus 8 
milliseconds in fetal receptors (10).  The orders in which the subunits are listed reflect the 
order of their arrangement when assembled.  No two identical receptor subunit types sit 
adjacent to each other.  This will become relevant later in the discussion. 
 Although the mechanism by which the loss of self-tolerance occurs is not yet 
understood, much is known about the nature of the autoantibodies, the antigen against 
which they are directed, and the mechanisms by which these factors disrupt the 
neuromuscular junction.  
The presence of autoantibodies against skeletal muscle AChRs is one of the 
hallmarks of myasthenia gravis.  The most convincing piece of evidence to support this is 
that patients that undergo plasma exchange to remove these antibodies often experience a 
dramatic improvement in symptoms (11).  These antibodies, depending on epitopic 
specificity, can bind and crosslink receptor subunits in such a way as to cause the 
receptors to be internalized and degraded in a process known as receptor modulation.  
They may also functionally block the binding of the neurotransmitter acetylcholine 
(ACh), or initiate complement fixation and cause disruption of the postsynaptic cell 
membrane (12). 
Approximately 50% of the antibodies produced in both experimental animals 
immunized with native α1 subunits and in MG patients are directed against the Main 
Immunogenic Region (MIR) of the α1 subunit.  The MIR is a highly conformational-
dependent epitope and immunization with denatured α1 subunits will not elicit the same 
MIR-oriented immunological response (9).  Antibodies directed against the MIR neither 
allosterically nor competitively prevent the binding of the neurotransmitter with the 
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receptor.  Their pathogenicity stems from their ability to crosslink receptors.  Each 
receptor has two α1 subunits, and thus two MIRs on prominent spurs that jut out from the 
main body of each subunit domain.  This structural feature of the molecule may be 
responsible for its immunogenicity, subjecting it to detection by potentially autoreactive 
immune cells (12) (Figure 1).  
Each receptor has two MIRs on roughly opposite sides of the molecule, and each 
MIR autoantibody has two antigen binding sites. Binding of antibodies to adjacent 
receptors causes the internalization and degradation of the bound receptors with a net loss 
from the muscle cell surface (receptor loss outpaces receptor expression) (9).  Antibodies 
directed against the MIR are quite pathogenic in that they can cause receptor loss in 
muscle cell cultures and induce weakness if injected into experimental animals (9). 
 Blockage of the ACh binding site is an important pathogenic mechanism in 
myasthenia gravis. Each skeletal muscle AChR has two ACh binding sites, in fetal 
receptors at the α1:δ and α1:γ subunit junctions and in adult receptors at the α1:δ and 
α1:ε subunit junctions.  Acetylcholine must occupy both sites on a receptor for proper 
function. Antibody occluding either or both sites is sufficient to inactivate the receptor 
(9).  In Experimental Autoimmune Myasthenia Gravis (EAMG), AChR blocking 
antibodies cause an acute form of MG lacking NMJ inflammation and necrosis. In 
patients, these types of antibodies likely explain the “Mary Walker phenomenon” which 
bears the name of the English neurologist that described it. The nature of this 
phenomenon is that MG patients treated with cholinesterase blockers and subjected to  
vigorous exercise quickly have weakness appear in muscles that were not exercised.  This 




Figure 1. Acetylcholine receptor structure: A) Top view of adult AChR receptor subunit 
orientation, ion channel (center) and ACh binding sites. B) Diagram of α1 receptor 
subunit. Springer/Kluwer Academic Publishers. Exploring the Vertebrate Central 
Cholinergic Nervous System. 2007. Pages 209-235. Neuronal Nicotinic Receptors: 
History, Structure, and Functional Roles. Jon Lindstrom. With kind permission of 




displaced from the receptor when its ligand (ACh) is in sufficient concentrations due to 
presynaptic neuronal release and cholinesterase inhibition (12). 
Activation of complement at the NMJ is also an important cause of pathological 
changes.  Inflammation of, and damage to the postsynaptic membrane causes remodeling.  
This results in not only the loss of furrowing and a decrease in the amount AChRs, but 
also the loss of voltage gated sodium channels which in turn leads to an increase in the 
action potential threshold for the muscle cell (11). 
 In many patients in whom AChR antibodies cannot be detected, Muscle Specific 
N terminus 









?1 ? ACh binding site at subunit interface 
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Kinase (MuSK) is the main autoantigen.  In these patients, MuSK antibodies disrupt the 
agrin/MuSK/rapsyn clustering pathway, leading to ineffective presentation of AChRs and 
muscle weakness. Mice that lack agrin or MuSK die at birth due to profound muscle 
weakness and their muscle cells show uniform AChR and rapsyn distribution (7). 
 The thymus likely plays a role in the pathogenesis of MG, but the mechanisms are 
not yet fully defined.  Most MG patients show thymic histological abnormalities, and of 
these patients, 70% exhibit thymic lympho-follicular hyperplasia (TFH) that resembles T 
and B cell germinal centers normally present in only peripheral lymphoid organs.  
Xenograft of fragments of these abnormal thymi into severe combined immune deficient 
(SCID) mice results in production of human AChR antibodies in the mice.  Thymectomy 
in MG patients has also been shown to improve the course of disease (12).  
Effects of cytokines on pathogenesis of the disorder also appear to be significant. 
Lymphoid cells isolated and cultured from thymomae of MG patients produce 
neutralizing antibodies against the cytokines interferon-α and interleukin-12.  If thymoma 
recurs, these antibodies are produced in higher concentration than AChR antibodies 
suggesting a strong link between anti-cytokine antibodies and thymoma (13). 
Proinflammatory cytokines such as tumor necrosis factor-α and interferon-γ upregulate 
expression of AChR, possibly allowing more rapid AChR sensitization once an 
inflammatory response is initiated (14). 
 Thymoma is found in 10-15% of MG patients.  It is important to distinguish 
between thymoma (thymic epithelial neoplasm) and thymic carcinoma, which resembles 
malignancies from other regions of the body.  Only thymomas retain the ability to 
selectively promote intratumorous T-cell development, and only thymomas are associated 
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with paraneoplastic myasthenia gravis (15).  Of patients with thymoma, 10-15% exhibit 
paraneoplastic syndromes other than MG, and 4-7% of patients with thymoma and MG 
exhibit more than one paraneoplastic syndrome (5).  
 As mentioned previously, the mechanism that causes the initial loss of 
discrimination between self and foreign antigen and initiates autoimmunity is unknown. 
However, there are several hypotheses that may help explain the problem in the future.  
One model is that molecular mimicry can induce potentially autoreactive CD4+ T cells to 
initiate a reaction.  Potentially autoreactive CD4+ T cells escape clonal deletion during 
immune system development and in normal individuals never induce a significant 
autoimmune response.  Microbial antigen fragments can resemble self-antigens and 
induce potentially autoreactive cells into full autoimmunity (12). 
 A second model is that a microbial superantigen (SAG) could cause loss of 
tolerance.  In a hyperplastic thymus, there is an abnormal number of dendritic cells (DCs) 
around which cluster CD4+ T cells. A DC infected with a SAG-producing virus or 
bacterium could then activate AChR-reactive CD4+ T cells, which would then migrate to 
the lymph nodes and activate B cells (12). 
 Lastly, a viral infection of muscle tissue could cause cross-presentation of self-
antigen to potentially autoreactive CD4+ T cells that, in the presence of proinflammatory 











 Epidemiological studies of MG have been ongoing since the 1950s, and findings 
for prevalence of the disease range from 0.5 to 20.4 per 100,000 individuals.  No areas of 
high or low incidence have been identified, no disease clustering can be identified, and 
the course of disease seems to be rather uniform.  Most studies have been on white 
populations of western European descent (16). 
 Phillips et al. (16) performed a study in Virginia in the mid-1980s and found MG 
prevalence around 14 per 100,000, with a female to male ratio of 1.5:1, and median onset 
age for women of 41.7 years and 60.3 years for men.  This study confirms the truism that 
MG generally affects women earlier in life than men (14). 
 Prevalence of MG has also been steadily increasing for the last several decades, 
most likely due to a combination of improved surveillance, awareness of the disease and 
improved treatments allowing patients to live longer (14). 
 Annual incidence of MG is 3-5 per million with a higher prevalence seen in urban 
areas versus rural (4). 
 Seronegative Myasthenia Gravis (SNMG) is MG where there are no detectable 
levels of AChR antibodies.  Roughly 15% of generalized MG patients fall into the 
SNMG category, while 50-60% of ocular MG patients are seronegative.  Hoch et al. 
reported in 2000 that some SNMG patients had MuSK antibodies, and it has since been 
found that 30-70% of SNMG patients are positive for MuSK antibodies (14). 
 In 2009, Alshekhlee et al. published a study using a nationwide database of 
inpatient disease classification codes to identify patients with diagnosis of myasthenic 
crisis (17).  Of 5,502 patients, the authors found that the incidence in women was two to 
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three times higher than men in the first 5 decades of life.  Men, however, had a higher 
incidence than women in the 6th, 7th, and 8th decades of life.  The overall mortality rate for 
MG while hospitalized was 2.2%, with a mortality rate of 4.47% for those patients 
experiencing myasthenic crisis (17).  
 
 
Clinical Diagnosis and Laboratory Testing 
 
 Clinical diagnosis of MG is carried out by first recording an accurate patient 
history, taking note of periods of fluctuating weakness.  The historical data is then 
corroborated with data from physical exams and laboratory studies. 
 Pharmacological testing can assist in diagnosing myasthenia gravis. Edrophonium 
chloride (Tensilon) is an acetylcholinesterase inhibitor with onset of action of about 30 
seconds and duration of about 5 minutes.  Edrophonium temporarily increases the amount 
of ACh at the NMJ, and allows the clinician to observe recovery of function in 
myasthenic patients.  This test is most useful in patients with symptoms of ocular MG 
where muscle performance may be measured objectively (3).  Care must be taken when 
administering edrophonium, as there is a risk for bronchospasm, bradychardia, and 
extreme gastrointestinal side effects. Sensitivity for edrophonium testing is about 90%, 
specificity is not easy to determine due to improved function after administration in other 
neuromuscular diseases.  Neostigmine is another acetycholinesterase inhibitor of longer 
duration that is an alternative for testing in children (5). 
 Electrophysiological testing directly stimulates the nerve side of the NMJ and 
measures the response of the muscle.  One such study is termed repetitive nerve 
stimulation (RNS).  In such a study, a motor nerve is stimulated at a low rate of 2-5 Hz, 
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which depletes the stores of ACh at the neuromuscular junction.  This reduces the 
likelihood of an action potential reaching the muscle, and causes failure of some of the 
transmissions.  These decremental responses are compared to baseline values, and the test 
is considered positive if there is a decrease of more than 10% between the baseline and 
4th stimulation (3). 
 Care must be taken in RNS that no acetylcholinesterase inhibitors be given for at 
least 12 hours prior to the RNS test; that proximal muscles such as the facial, trapezius, or 
deltoid muscles be avoided as they are more likely to give erroneous results; and that 
careful attention to proper technique be paid.  If performed properly, RNS testing only 
shows a sensitivity of 60% for myasthenia gravis (3). 
 Single fiber electromyography (SFEMG) is a technique in which multiple muscle 
fiber responses are measured from stimulation of a single nerve.  The difference in time 
to contract between individual fibers is called the neuromuscular jitter.  This technique 
should always be performed in a clinically weak muscle.  Usually testing is begun in the 
extensor digitorum communis muscle, if findings there are normal then a facial muscle 
should be studied next.  When limb and facial muscles are studied in conjunction, 
SFEMG shows 97% sensitivity for myasthenia gravis.  Other neuromuscular disorders 
will produce abnormal transmission results, and SFEMG must be performed by a 
qualified expert using specialized equipment to ensure result validity (3). 
 Serological assays for AChR binding, blocking and modulating antibodies exist. 
One of the most useful in clinical practice is the AChR binding antibody assay.  This is a 
radioimmunoprecipitation assay that uses soluble AChR labeled with radio labeled 125I α-
bungarotoxin (BGTX).  Patients with early-onset MG with generalized weakness tend to 
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have the highest responses with this assay format (18). 
 The soluble receptor used in the AChR binding assay and the heterogeneous 
nature of patients’ antibody profiles can make detection of antibodies in patients vary.  
One source of receptor for this assay is the TE671 cell line, a human rhabdomyosarcoma 
(RD) cell that expresses fetal acetylcholine receptor (20); another source is human 
cadaver muscle.  The effect of soluble receptor source was studied at ARUP Laboratories 
in SLC, Utah. The study included three receptor sources: human muscle extract, RD cell 
extract, and an 80/20% mixture of RD/muscle extract. Findings were that for 96% of 
patients, there was no difference in result.  For 4% of patients, however, result 
interpretation changed depending on pure receptor source and the highest sensitivity was 
attained with the mixture (20). 
 Acetylcholine receptor blocking antibodies can be measured by their ability to 
inhibit binding of BGTX in culture.  There is some debate as to whether these antibodies 
competitively block the neurotransmitter binding site, or if they allosterically inhibit the 
toxin binding (18). 
 Acetylcholine receptor modulating antibodies can be measured by exposing 
BGTX labeled RD cells in culture to sera from MG patients.  Radiolabeled receptors will 
be internalized and degraded, and the ratio of radioactivity in the culture supernatant 
versus the cell pellet can be used to determine percent receptor modulation (21). 
 Recent research has focused on flow cytometric methods for determining the 
presence of AChR modulating antibodies, as well as possibly binding and blocking 
antibodies.  These methods use fluorescent labels rather than radiolabels, thereby 
eliminating a regulatory and environmental burden (19). 
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 A meta-analysis of literature surveying efficacy of MG testing found that 
edrophonium testing was reported to be 92% sensitive for ocular MG and 88% sensitive 
for generalized MG, and 97% specific for both forms of disease.  The variability in the 
selection of nerve-muscle pairs tested in RNS studies made it impossible to draw 
conclusions regarding testing outcomes for this method.  However, generally the data 
suggested that RNS is a poor diagnostic tool for ocular MG and outcomes being better for 
generalized MG if multiple muscle-nerve pairs are tested.  Although there was some 
question as to whether the methodology was practiced effectively in all studies, SFEMG 
sensitivity and specificity were high for ocular MG but data were limited for generalized 
MG, yet did demonstrate high specificity.  For antibody studies, the authors did not 
differentiate AChR binding, blocking, or modulating antibodies.  Antibody testing 
showed 96% sensitivity for generalized MG, and 44% sensitivity for ocular MG.  Very 
good specificity of 98-99% was reported for antibody testing in any form of myasthenia 
gravis (22).  
 
 
Treatment and Outcomes 
 
 Without treatment, MG progresses in most patients and 66% of those initially 
presenting with ocular symptoms will progress to generalized myasthenia gravis.  After 2 
years, 14% will remain with strictly ocular symptoms.  Those left untreated will 
experience progressive weakness involving more muscle groups with some developing 
fixed weakness with muscle atrophy, while 25-31% will succumb to the disease (23).  
Advances in disease treatment and maintenance over the past few decades, however, have 
essentially reduced mortality to zero (4). 
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The first tier treatment for MG involves cholinesterase inhibitors.  These drugs 
bind acetylcholinesterase reversibly, and have minimal central nervous system side 
effects since they do not readily cross the blood-brain barrier (5).  Pyridostigmine is one 
of the most frequently used inhibitor drugs as both initial therapy for new patients, and 
long-term therapy for patients with mild symptoms.  Adverse effects include GI tract 
hypermotility, increased sweating, excessive mucous membrane secretions, and muscle 
cramps. Caution should be exercised in administering cholinesterase inhibitors to MuSK 
antibody positive patients as they frequently have ACh hypersensitivity (24). 
 Plasma exchange involves removing antibodies from patient plasma via 
membrane filtration or centrifugation.  It can be used to alleviate symptoms on a short-
term basis in patients experiencing myasthenic crisis, to induce remission of symptoms 
prior to surgery, or to alleviate symptoms during the initiation of immunosuppressive 
therapy (24). 
 Intravenous immunoglobulin (IvIg) therapy is recommended for similar 
circumstances as that of plasma exchange, i.e., short term relief of serious symptoms.  No 
long-term benefit has been proven for IvIg in MG cases that are mild to moderate (24). 
 Thymectomy is of little benefit to patients with mild MG, but patients with more 
severe MG are 3.7 times more likely to undergo remission with surgery than without.  
Thymectomy is always indicated in MG patients with thymoma, and prognosis is 
dependent on early and complete removal of the tumor (24). 
 Immunosuppressive drugs are used in patients that do not respond well to other 
therapies.  The side effects of various immunosuppressants need to be monitored and 





 Due to the variability of initial symptoms, heterogeneity of patient autoantibody 
profiles, potential for grave complications as the disease progresses, and the need for the 
best available clinical laboratory results to aid in disease management, I investigated the 
possibility of adapting a new flow cytometric method for the detection of AChR 













Sera from 97 self-proclaimed normal healthy individuals and 118 samples 
submitted for AChR modulating antibody testing were de-identified and tested in 
accordance with University of Utah Institutional Review Board guidelines.  Rat anti-
human AChR monoclonal antibody 210 (mAb210) was purchased from Abcam 
(Cambridge, MA) and goat anti-rat IgG Alexa-488® secondary antibody was purchased 
from Invitrogen (Carlsbad, CA).  Human rhabdomyosarcoma (RD) cells (CCL-136; 
ATCC. Manassas, VA) expressing fetal AChRs were cultured in 175 cm2 flasks at 37°C, 
5% CO2, in a 95% humidity incubator to confluence.  Culture medium was purchased 
from ARUP Laboratories Reagent Lab (Salt Lake City, UT) and consisted of Eagle’s 
Minimal Essential Medium (EMEM) supplemented with 10% heat-inactivated Fetal 
Clone III, Minimal Essential Medium (MEM) essential and nonessential amino acids, and 
MEM vitamins.  Cells were harvested  from flasks using 1x phosphate buffered saline 
(PBS) containing 9mM ethylenediaminetetraacetic acid (EDTA), centrifuged at 500g for 
5 minutes at room temperature, decanted, resuspended in culture medium, counted, and 
normalized to a concentration of 1x106 cells per milliliter.  Harvested cells were 
dispensed into 96 well tissue culture plates at a concentration of 1x105 cells per well.  
Cells to serve as background secondary antibody or maximum receptor staining 
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standards were exposed to 4 µL cell culture medium (no serum exposure).  Assay control 
and test patient cells were exposed to 4 µL of the appropriate sera.  The plate was then 
incubated overnight at 37°C, 5% CO2, in a 95% humidity incubator.  The following 
morning the plate was decanted, cells were dissociated with cold PBS-EDTA, centrifuged 
at 500g for 5 minutes and washed with cold assay buffer (2% bovine serum albumin in 
HBSS without Ca2+ or Mg2+).  All cells were then labeled for 30 minutes on ice with 2 
µg/mL mAb210 in assay buffer, except background staining cells which received assay 
buffer alone.  Cells were then washed twice and labeled with 4 µg/mL Alexa-488® 
conjugated goat anti-rat IgG, including background staining cells.  Cells were again 
washed twice, resuspended in assay buffer, and analyzed on a BD FACSCanto II 
cytometer using Diva software.  Cell populations were gated to normalize fluorescence 
against nonspecifically stained cells and to exclude cell fragments and aggregates.  
Acetylcholine receptor percent modulation was calculated by comparing the proportion 
of gated cells that fell above the fluorescence cut-off to the maximally stained assay 
standard using the following equation: 
 
 




 Assay reference range was established by Receiver-Operator Characteristic 
(ROC) Curve analysis of flow cytometric versus current assay results. Area under the 
ROC curve (AUC) was evaluated as an indicator of assay performance. Software used for 
the ROC curve analysis was SAS Version 9.1 (SAS Institute, Inc. Cary, NC).  Results of 
the new assay were then compared to results of the current AChR modulating antibody 
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Sera from 120 self-proclaimed normal healthy individuals and 100 samples 
submitted for AChR modulating antibody testing were de-identified and tested in 
accordance with University of Utah Institutional Review Board guidelines.  Samples 
were assayed on both the fetal AChR-expressing RD cell line and the DB40 (Isis 
Innovation, Ltd. Oxford, UK) cell line for the presence of AChR modulating antibodies.  
The DB40 cell line is derived from the same rhabdomyosarcoma cell line as the RD cell, 
but has been transfected with genes for the AChR epsilon subunit, and thus expresses 
both fetal and adult acetylcholine receptors (19).  Both cell lines were separately cultured 
and plated as previously described, with the addition of 0.5 mg/mL geneticin (Gibco, 
Grand Island, NY) to the DB40 cell culture medium.  The AChR modulating antibody 
assay set-up and overnight incubation were retained for the adherent cell protocol, but 
assay procedure following the overnight incubation was modified to improve sensitivity, 
efficiency, and cell viability.  Following the overnight incubation to allow for AChR 
modulation, plates were decanted to remove patient and control dilutions and then 
inverted and gently blotted. Next, 100 µL of assay buffer (0.5% bovine serum albumin in 
HBSS without Ca2+ or Mg2+) were added to background stain wells, followed by addition 
of 100 µL of  2 µg/mL mAb210 in assay buffer to all remaining control and patient wells.  
Cells were incubated for 30 minutes in dark at room temperature and then gently washed 
twice with 200 µL of assay buffer.  Plates were then inverted and blotted. All cells were 
then stained with 100 µL 4 µg/mL APC-conjugated goat anti-rat IgG (BD Biosciences, 
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San Jose, CA) for 30 minutes in dark at room temperature.  Cells were again washed, and 
100 µL 9 mM EDTA-PBS was added and allowed to incubate 10 minutes in dark at room 
temperature.  Cells were then dissociated by pipetting, followed by the addition of 50 µL 
each of assay buffer and 1% paraformaldehyde in phosphate buffered saline.  The fixed 
cell suspension was then transferred to cytometer tubes and analyzed on a BD 
FACSCanto II cytometer using Diva software. 
Results for RD and DB40 cell AChR modulation were calculated according to 
three different schemes: 1) In Scheme A, cursor gates were set to normalize populations 
against background fluorescence.  The proportion of gated cells above background was 
taken as a measure of AChR expression.  Cell populations in control and test samples 
were then compared to a maximally stained assay standard.  2) Scheme B used the same 
gate settings and calculations as in Scheme A, but compared mean fluorescence of 
standard, control, and test sample cell populations rather than population distribution.  3) 
Scheme C compared fluorescence of all gated events in standard, control and test samples 
regardless of background fluorescence.  Result calculation for all three schemes used the 
equation previously described.  Reference ranges for all three calculation schemes on 
both cell lines were generated as previously mentioned and results were compared to the 
current clinical assay for assessment of performance. 
Serial two-fold dilutions of an AChR modulating antibody positive specimen 
were made in cell culture medium and tested for linearity and possible quantification. 
Results were calculated according to the scheme that provided optimal correlation with 
the current assay. 
Analytical specificity was assessed by testing 21 samples for AChR modulating 
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antibodies that also tested positive for anti-nuclear antibodies (ANA), voltage-gated 













Results of the ROC curve analysis suggested a positive cut-off of 54% 
modulation or greater (Figure 2).  This cut-off was increased to 60% to eliminate one 
false positive in the normal sample group (55% modulation). This adjustment did not 
yield any false negative results in the AChR modulating antibody positive samples.  
Result distribution is illustrated in Figure 3.  Result correlation between the suspension-
stained flow-cytometric assay and the current radioimmunoassay is illustrated in Figure 
4.  The ROC curve in Figure 2 shows an area under curve (AUC) value of 0.84, 
indicating good sensitivity and specificity at the 54% modulation cut-off.   
The result distribution illustrated in Figure 3 was calculated with the 60% 
modulation cut-off. The figure shows good separation between results of the normal 
donor samples and the majority of the AChR modulating antibody positive samples. 
However, the results from the clinical negative samples show a surprising number that 
test positive by the new assay.  One sample of the normal donors did test positive (62% 
AChR modulation).  It was later determined that this individual had been diagnosed with 
myasthenia gravis in the past, but the individual felt normal at the time of sample 
collection and symptoms were in remission.
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Figure 2. RD Cell Suspension-stained Receiver Operator Characteristic (ROC) analysis. 





Figure 3. RD Cell suspension-stained result distribution. Result distribution for the AChR 
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The linear regression plot in Figure 4 demonstrates poor result correlation (R2= 
0.49) between the new assay and the current assay due to the use of different reference 
ranges between the two assays and the disagreement in a number of qualitative results. 
Results for the flow cytometric assay were then compared qualitatively to those of 
the current AChR modulating and soluble AChR binding antibody assays.  When 
compared to the current modulating antibody assay, the new assay demonstrated 83% 
agreement, 90% sensitivity, and 81% specificity.  Compared to the soluble AChR binding 
assay, the new assay demonstrated 77% agreement, 65% sensitivity, and 93% specificity. 
The current AChR modulating antibody radioimmunoassay shows 64% agreement, 43% 
sensitivity, and 89% specificity against the soluble AChR binding assay.  These findings 




Figure 4. RD Cell suspension-stained result correlation. Result correlation between 
AChR modulating antibody suspension stain flow cytometric assay and the current 
radioimmunoassay. 
 
y = 1.216x + 34.641 
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Table 1: Comparison of performance of AChR modulating antibody 



















Results of the two AChR modulating antibody assays were compared to the 
AChR binding assay due to the wide acceptance of the binding assay as the most 
sensitive clinical laboratory test (25).  Overall, the flow cytometric assay shows better 
correlation with the AChR binding antibody assay than the current assay, but the actual 
values appear lower than desirable due to inclusion of samples with extraordinary result 
profiles.  Of the 118 clinical samples included in this part of the study, 65 were samples 
that were selected due to discrepant AChR antibody results (positive binding, negative 
modulating, or vice versa).  Within the group of clinical samples, 33 displayed discrepant 
qualitative results between either the new flow cytometric assay, the current 
radioimmunoassay, or the soluble AChR antibody assay.  However, 26 of these 33 
discrepant samples were negative by the current assay and positive by the new flow 
cytometric assay with one or more corroborating positive results from other AChR 
antibody assays.  
  
Agreement  Sensitivity Specificity 
AChR modulating 
antibody suspension-stain 
vs. AChR modulating 
antibody RIA 
84% 91% 81% 
AChR modulating 
antibody suspension-stain 
vs. AChR binding 
antibody 
78% 66% 93% 
AChR modulating 
antibody RIA vs. AChR 
binding antibody 





 Based on the experiences with the suspension-stained cells, the following was 
observed: 1) the cell line used is adherent, and when dissociated is apparently readily 
subject to anoikis; 2) the suspension staining was initially conducted on ice in an attempt 
to minimize AChR loss due to turnover, but colder temperatures were observed to have a 
profoundly negative effect on cellular integrity; 3) there was a sub-optimal separation of 
receptor-associated fluorescence between background and maximally stained cell 
populations; and 4) any time interval between finishing cellular preparation and 
instrument analysis had a deleterious effect on cellular integrity. 
 In response to these observations the procedure was changed to be performed at 
room temperature with cells still attached in a culture plate, a brighter fluorophore-
labeled secondary antibody was used, and cells were paraformaldehyde-fixed 
immediately following staining and dissociation steps.  Effects of these modifications can 
be seen in Figure 5. 
The effects of the assay modification illustrated in Figure 5 show a much larger 
proportion of cells that stain above background fluorescence (population to the right of 
the cursor gate).  The proportion of cells staining above background prior to assay 
modification was approximately 10% of gated events and increased to approximately 
30% after modification.  This is attributed mostly to improved cellular integrity due to 
being kept closer to physiological temperature and remaining attached to a solid substrate 
during staining.  This increase in cell staining most likely contributes to the robustness, 
sensitivity, and reproducibility of the assay. 





Figure 5. Effects of assay procedure modification. A) Maximally stained assay standard 










calculation schemes for the two cell lines can be found in Table 2. 
The values in Table 2 show that any one of the three calculation strategies 
combined with either of the two cell lines provides results that compare favorably with 
the current assay.  However, the RD cell line when combined with result Calculation 
Scheme B provided the closest result match to the current assay.  For the DB40 cell line, 
Calculation Scheme B also provided the most favorable result comparison with the 
current assay.  
 Results of adherent RD cell ROC curve analysis are illustrated in Figure 6.  Result 
distribution for RD cell adherent stain Calculation Scheme B is illustrated in Figure 7.  
Result correlation of adherent RD cell adherent stain Calculation Scheme B with those of 
the current assay is illustrated in Figure 8.  
The ROC curve plot in Figure 6 shows an AUC value of 1.00, indicating very 
good sensitivity and specificity for adherent RD cell AChR modulating antibody results. 
Figure 7 illustrates AChR modulating antibody result distribution for the RD cell 
line calculated using mean population fluorescence after background staining 
normalization (Scheme B).  Positive cut-off for this calculation scheme was determined 
by ROC analysis to be 46% modulation or greater.  This figure illustrates the stark 
separation of results for negative and positive samples.  The majority of the normal and 
AChR modulating antibody negative sample results display little to no receptor 
modulation while the majority of the positive samples display near-complete to complete 
receptor modulation.  This separation of result populations suggests a good dynamic 
range for the assay with less potential for false negative or false positive results. 





       Table 2. Qualitative performance evaluation results for the AChR modulating 
         antibody assay on adherent RD and DB40 cell lines versus the current assay. 
RD Cell Agreement Sensitivity Specificity 
Calculation Scheme A 97% 90% 99% 
Calculation Scheme B 99% 98% 99% 
Calculation Scheme C 95% 90% 96% 
DB40 Cell    
Calculation Scheme A 91% 82% 94% 
Calculation Scheme B 97% 94% 98% 






Figure 6. RD cell adherent-stained ROC analysis. Receiver Operator Characteristic curve 
for AChR modulating antibody RD cell adherent stain results versus results from the 











Figure 7. RD cell adherent-stained result distribution. Result distribution for adherent RD 
cells calculated using mean fluorescence of gated cells after background fluorescence 





Figure 8. RD cell adherent-stained result correlation. Results correlation with the current 
assay.  Results calculated using mean fluorescence of gated cells after background 
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 between results for RD cell Calculation Scheme B and those of the current assay. 
Results of adherent DB40 cell ROC curve analysis are illustrated in Figure 9.  
Result distribution for DB40 Cell Calculation Scheme B is illustrated in Figure 10.  
Result correlation of adherent DB40 Cell Calculation Scheme B with those of the current 
assay is illustrated in Figure 11.  
The ROC curve plot in Figure 9 shows an AUC value of 0.97, indicating very 
good sensitivity and specificity for adherent DB40 cell AChR modulating antibody 
  
 
Figure 9. DB40 cell adherent-stained ROC analysis. ROC curve for AChR modulating 
antibody DB40 cell adherent stain results versus results from the current assay. Positive 





Figure 10. Flow cytometric result distribution for adherent DB40 cells calculated using 






Figure 11. DB40 cell adherent-stained result correlation. Results correlation with the 
current assay.  Results calculated using mean fluorescence of gated cells after 
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The ROC curve plot in Figure 9 shows an AUC value of 0.97, indicating very 
good sensitivity and specificity for adherent DB40 cell AChR modulating antibody 
results. 
Figure 10 illustrates AChR modulating antibody result distribution for the DB40 
cell line calculated using mean population fluorescence after background staining 
normalization (Scheme B).  Positive cut-off for this calculation scheme was determined 
by ROC analysis to be 25% modulation or greater.  Results for normal donor and AChR 
modulating antibody  negative samples show little to no receptor modulation while the 
majority of the positive results show a high amount (>70%) modulation.  Only three 
clinical positive samples resulted as false negative in relation to the current assay. 
The linear regression plot in Figure 11 shows fair result correlation (R2= 0.73) 
between results for DB40 cell Calculation Scheme B and those of the current assay. 
Results for the linearity study are illustrated in Figure 12. 
The AChR modulation response from the dilution series yielded strong responses 
for four two-fold dilutions.  No dilution result fell below the 46% modulation positive 
cut-off value.  Results from the dilution series were evaluated using the statistical 
program EP Evaluator and found to be nonlinear. 
Results for analytical specificity are summarized in Table 3.  Analytical 
specificity was found to be 100%.  All AChR modulation results were negative for the 

























































Table 3. Results for analytical specificity 
NMD Ab= Neuromuscular disease antibody.  ANA=Anti-nuclear antibody.   VGCC= 
Voltage-gated calcium channel antibody.  VGKC= Voltage-gated potassium channel 
antibody.  Reference range for AChR modulating antibody assay is <=45% 
 
 
Sample Type Clinical Result % AChR Modulation by Flow
NMD Ab Positive VGKC Pos 3
NMD Ab Equiv VGKC +/= 3
NMD Ab Positive VGKC Pos 0
NMD Ab Equiv VGKC +/= 6
NMD Ab Positive VGKC Pos 0
NMD Ab Positive VGKC Pos 1
NMD Ab Positive VGCC Pos 0
NMD Ab Positive VGCC Pos 0
NMD Ab Positive VGCC Pos 1
NMD Ab Positive VGCC Pos 0
NMD Ab Positive VGCC Pos 4
ANA Positive 1:160 Nucleolar 1
ANA Positive 1:320 Nucleolar 2
ANA Positive 1:320 Speckled 0
ANA Positive 1:160 Centromere 0
ANA Positive 1:160 Homogenous/Speckled 0
ANA Positive 1:2560 Centromere 0
ANA Positive 1:160 Homogenous 10
ANA Positive 1:1280 Speckled 6
ANA Positive 1:160 Homogenous/Speckled 22











 Due to the protocol used for the initial suspension-stained cell results, the cells 
tested experienced adverse conditions which negatively affected cellular integrity.  These 
conditions were cold temperature and being in fluid suspension.  This led to several assay 
failures and variable results (data not included) which brought the utility of this assay 
format into question.  However, after several trials it became apparent how the RD cell 
could be made to perform consistently even under adverse conditions.  The sample set 
used for the suspension-stain portion of the study was of note due to the fact that, as 
previously mentioned, 65 of the 118 clinical samples had discrepant AChR antibody test 
results (e.g., positive binding antibodies, negative modulating antibodies or vice versa).  
The remaining 53 clinical samples were either negative or positive for all available AChR 
antibody testing.  It was encouraging to see that for samples that had discrepant 
modulating antibody flow cytometric and RIA results, the majority (26 of 33) were 
positive by the flow cytometric assay and had other positive AChR antibody results to 
corroborate.  This suggests that the flow cytometric assay is more sensitive and robust, 
given that the AChR modulation effect was still demonstrated under adverse conditions.  
The suspension-stain flow results demonstrated lower sensitivity (91%) and agreement 
(84%) compared to the current assay due to inclusion of these discrepant results.  
However, when compared to the more sensitive AChR binding antibody assay, the 
current AChR modulating antibody radioimmunoassay shows 45% sensitivity while the
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flow cytometric assay shows 66% sensitivity.  Results for the normal donor samples 
show a lack of unexplained positive results suggesting good specificity.  These 
observations suggest that the flow cytometric assay is a more sensitive, robust assay than 
the current format. 
 Experiences with staining RD cells in suspension made apparent the need to 
modify the assay format to improve cellular integrity prior to analysis.  These 
modifications mostly consisted of performing the assay at room temperature without 
dissociating cells prior to staining.  This resulted not only in improving cellular integrity 
but also greatly improving assay efficiency.  The improved cellular integrity led to 
brighter cells due to better receptor retention in conjunction with use of the brighter APC 
fluorophore. 
 Samples used for the suspension-stain portion of the study were unavailable when 
testing commenced on the adherent-stain portion of the assay.  The clinical samples 
tested in the second part of the study demonstrated more conventional result profiles, i.e., 
either positive or negative for all available AChR antibody testing.  The use of these more 
conventional samples led to smaller differences in assay performance, but did not hinder 
evaluation. 
 The result calculation strategy in which background stain-normalized 
fluorescence was used (Calculation Scheme B) provided results that correlated most 
favorably with the current assay for both the RD and DB40 cell lines (Table 2).  The two 
alternative calculation strategies seemed to either elevate results of normal donor and 
clinical negative samples or suppress results of clinical positive samples.  The DB40 cell 
line demonstrated slightly lower sensitivity than the RD cell line, possibly due to defects 
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in receptor turnover or metabolism subsequent to gene transfection.  It may be 
worthwhile to assess the effect of increased patient serum exposure concentration on the 
DB40 cell line as a means of increasing sensitivity in the future. 
 Results for the positive sample dilution series did not display linearity.  Further 
investigation of a means of quantifying AChR modulating antibodies is not warranted 
based on these data.  Due to the heterogeneous nature of autoantibody responses across 
patient populations combined with varying degrees of symptoms and serological results 
(12), it is reasonable to assume it would prove difficult to correlate the quantity of these 
antibodies with their effect. 
  Results for the analytical specificity showed no cross-reactivity in samples that 
tested positive for other neuromuscular disease antibodies (voltage-gated calcium and 
potassium channel antibodies) or for connective tissue disease (anti-nuclear) antibodies.  
These potential confounding conditions are not comprehensive, but results from these 
samples clearly suggest that interference from immune-mediated disorders other than 











 Detection of AChR modulating antibodies by flow cytometry is a viable 
alternative to the current radioimmunoassay.  Results from the RD cell line correlate best 
with the current assay when calculated using mean population fluorescence attenuated for 
nonspecific secondary antibody staining and inherent cell fluorescence.  Of 170 samples 
tested, only 2 showed results that differed qualitatively with the current assay.  One self-
proclaimed healthy donor sample tested positive by the current modulating antibody 
assay and negative by the new modulating antibody assay (likely false positive). The 
other was an AChR antibody sample that tested negative by the current modulating 
antibody assay but positive by the new modulating antibody assay.  This result was likely 
a false negative since the sample showed positive AChR binding and blocking antibody 
results to corroborate.  Compared to the current radioimmunoassay, sensitivity and 
specificity of the DB40 cell line were 94% and 98%, respectively.  The RD cell line 
showed 98% sensitivity and 99% specificity.  Based on these data, and when taking into 
account increased costs associated with acquisition and maintenance, use of the DB40 
cell line for this application is not warranted. 
 This new assay format not only exceeds performance of the current assay, but also 
allows for the quantification of receptor expression on the RD cell facilitating more 
objective measurement of assay performance.  This enhanced assay performance 
monitoring will likely lead to less run failures and delays in reporting clinical results due
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 to cell line failure. One last advantage of the new assay format is the ability to truly 
differentiate AChR modulating from AChR blocking antibodies.  Both modulating and 
blocking antibody assay formats rely on 125I α-bungarotoxin to label and quantify 
acetylcholine receptors, and AChR blocking antibodies can displace 125I α-bungarotoxin 
leading to elevated AChR modulating antibody results.  By labeling the Main 
Immunogenic Region of AChR α-subunits with a monoclonal antibody, the chance of 











1. Hughes T. The early history of myasthenia gravis. Neuromuscul Disord 2005;12:878-
86. 
 
2. Musilek K, Komloova K, Zavadova V, Holas O, Hrabinova M, Pohanka M, et al. 
Preparation and in vitro screening of symmetrical bispyridinium cholinesterase 
inhibitors bearing different connecting linkage-initial study for myasthenia gravis 
implications. Bioorg Med Chem Lett 2010;20:1763-6. 
 
3. Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis 2007;2:44. 
 
4. Kuks JBM. Clinical presentation and epidemiology of myasthenia gravis. In: Kaminski 
HJ, editor. Myasthenia gravis and related disorders. 2nd Ed. New York: Humana 
Press; 2009. p. 79-94. 
 
5. Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other 
paraneoplastic syndromes. Hematol Oncol Clin North Am 2008;22:509-26. 
 
6. Jacob S, Viegas S, Lashley D, Hilton-Jones D. Myasthenia gravis and other 
neuromuscular junction disorders. Pract Neurol 2009;9:364-71. 
 
7. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. 
J Clin Invest 2006;116:2843-54. 
 
8. Ubogu EE, Ruff RL. Neuromuscular junction physiology and pathophysiology. In: 
Kaminski HJ, editor. Myasthenia gravis and related disorders. 2nd Ed. New York: 
Humana Press; 2009. p. 1-12. 
 
9. Lindstrom JM. Acetylcholine receptor structure. In: Kaminski HJ, editor. Myasthenia 
gravis and related disorders. 2nd Ed. New York: Humana Press; 2009. p. 13-41. 
 
10. Newland CF, Beeson D, Vincent A, Newsom-Davis J. Functional and non-functional 
isoforms of the human muscle acetylcholine receptor. J Physiol 1995;489:767-78. 
 
11. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and 
biological heterogeneity. Lancet Neurol 2009;8:475-90.
43 
 
12. Conti-Fine BM, Diethelm-Okita B, Ostlie N, Wang W, Milani M. 
Immunopathogenesis of myasthenia gravis. In: Kaminski HJ, editor. Myasthenia 
gravis and related disorders. 2nd Ed. New York: Humana Press; 2009. p. 43-70. 
 
13. Shiono H, Wong YL, Matthews I, et al. Spontaneous production of anti-IFN-alpha 
and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients 
suggests autoimmunization in the tumor. Int Immunol 2003;15:903-13. 
 
14. Poëa-Guyon S, Christadoss P, Le Panse R, Guyon T, De Baets M, Wakkach A, et al. 
Effects of cytokines on acetylcholine receptor expression: implications for 
myasthenia gravis. J Immunol 2005;174:5941-9. 
 
15. Strobel P, Chuang WY, Marx A. Thymoma-associated myasthenia gravis. In: 
Kaminski HJ, editor. Myasthenia gravis and related disorders. 2nd Ed. New York: 
Humana Press; 2009. p. 105-117. 
 
16. Lanford JW, Phillips LH. Epidemiology and genetics of myasthenia gravis. In: 
Kaminski HJ, editor. Myasthenia gravis and related disorders. 2nd Ed. New York: 
Humana Press; 2009. p. 71-78. 
 
17. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and 
mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 
2009;72:1548-54. 
 
18. Agius MA, Richman DP, Vincent A. Autoantibody testing in the diagnosis and 
management of autoimmune disorders of neuromuscular transmission and related 
diseases. In: Kaminski HJ, editor. Myasthenia gravis and related disorders. 2nd Ed. 
New York: Humana Press; 2009. p. 143-156. 
 
19. Keefe D, Hess D, Bosco J, Tzartos S, Powell J, Lamsa J, Josiah S. A rapid, 
fluorescence-based assay for detecting antigenic modulation of the acetylcholine 
receptor on human cell lines. Cytometry B Clin Cytom 2009;76:206-12. 
 
20. Haven TR, Lyons BW, Pasi BM, Wu LL, Astill ME, Hill HR. Effect of acetylcholine 
receptor source on detection and quantification of anti-acetylcholine receptor-binding 
antibody [Letter]. Clin Chem 2008;54:1580-1. 
 
21. Lyons BW, Wu LL, Astill ME, Wu JT. Development of an assay for modulating anti-
acetylcholine receptor autoantibodies using human rhabdomyosarcoma cell line. J 
Clin Lab Anal 1998;12:315-9. 
 
22. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. 
Neuromuscul Disord 2006;16:459-67. 
 




24. Skeie GO, Apolstolski S, Evoli A, Gilhus NE,Illa I, Harms L, et al. Guidelines for 
treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 
2010;17:893-902. 
 
25. Haven TR, Astill ME, Pasi BM et al. An algorithm for acetylcholine receptor 
antibody testing in patients with suspected myasthenia gravis [Letter]. Clin Chem 
2010 Jun;56:1028-9. 
